MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

MaxCyte Inc.

MaxCyte ( ($MXCT) ) has provided an announcement. On March 23, 2026, MaxCyte announced the appointment of Parmeet Ahuja as Chief Financial Officer ...

MaxCyte Appoints New Chief Financial Officer Ahuja

The latest announcement is out from MaxCyte ( ($MXCT) ). On March 24, 2026, MaxCyte reported fourth-quarter 2025 revenue of $7.3 million, down 16% ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	MXCT	$0.75	+6.29%	715.77K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	MXCT	$0.75	+6.3%	715.77K
3
4
5
6

MXCT

MXCT

No Data Available

Get MaxCyte Inc. Data in Excel

Get MaxCyte Inc. Data in Excel